1. Which of the following is true regarding HER2+ breast cancer?

2. LG is a 38-year-old female who presents to the clinic with a new right breast mass. CT evidence of 4 small hepatic lesions consistent with metastasis. Immunohistochemistry is positive for HER2/neu amplification (3+). What therapy regimen do you recommend for LG?

3. What second-line treatment would you recommend for a metastatic breast cancer patient who progressed on trastuzumab and paclitaxel?

4. What toxicity prevention and monitoring is recommended while on trastuzumab deruxtecan?

« Return to Activity